Viatris has penned a deal worth $2bn to offload “substantially all” of its OTC assets but has decided to retain select consumer health products and Rx-to-OTC switch candidates, including erectile dysfunction treatment Viagra.
Viatris is bucking the trend of major pharma players exiting the consumer health market by partially reversing its decision to divest its OTC business.
The Canonsburg, PA-based firm described OTC as “non core” in November 2022 as it put the business up for sale...
Create an account to read this article
Already a subscriber?
The global ingredients supplier has recently launched microbiome-focused products to expand its supplements offering and has more innovations in the pipeline.
Swedish probiotics player BioGaia is reaping the benefits of increased marketing investments and distribution in the US.
HBW Insight speaks to Prime Fifty founder and managing director Max Gowland about the science behind healthy aging and the opportunity for the consumer health industry.
Nature’s Bounty, Osteo Bi-Flex and Puritan’s Pride are among the dietary supplement brands under strategic review by Nestle as the firm shifts its focus to the premium end of the market.
The global ingredients supplier has recently launched microbiome-focused products to expand its supplements offering and has more innovations in the pipeline.
Divesting C&D’s vitamin business, says CEO Richard Dierker, is “probably the cleanest option” as brands remain a drag on earnings after second quarter.
Centrum Vitamin D Boost combines a wide range of daily vitamins with a 30-microgram dose of vitamin D, delivering six times more of the micronutrient than the firm’s Centrum Advance.
